The President of Tianjin SmithKline Beecham Pharmaceutical Ltd. recently revealed that he anticipates that annual sales of the company to reach RMB 2.2 billion in 2005, among which OTC drug sales will account for 80%.  The company's Contac is China's No.1 OTC cold medication, has an annual sales of RMB 300 million. The company's objective is to overtake Xian Janssen and become the leader of the Chinese pharmaceutical market within five to six years.

OTC drug sales also contributes 64% of Xian Janssen's annual business.